Research programme: glycogen synthase kinase 3 beta inhibitors

Drug Profile

Research programme: glycogen synthase kinase 3 beta inhibitors

Alternative Names: 9 ING 41

Latest Information Update: 11 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Northwestern University; University of Illinois at Chicago
  • Developer Actuate Therapeutics; Northwestern University; University of Illinois at Chicago
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Preclinical Glioblastoma; Inflammation; Neuroblastoma

Most Recent Events

  • 07 Mar 2017 Research programme: glycogen synthase kinase 3 beta inhibitors is available for licensing as of 07 Mar 2017. https://actuatetherapeutics.com/partnering/
  • 07 Mar 2017 Preclinical trials in Inflammation in USA (unspecified route) before March 2017
  • 07 Mar 2017 Actuate Therapeutics plans the first-in-man phase I trial of 9 ING 41, presumably in Glioblastoma, in early 2017 (Actuate Therapeutics website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top